Hudson Bay Capital Management
IOVA icon

Hudson Bay Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

Hudson Bay Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-135,000
Closed -$1.27M – 1007
2024
Q3 		$1.27M Sell
135,000
-115,000
-46% -$1.09M 0.01% 625
2024
Q2 		$2M Buy
250,000
+200,000
+400% +$2.14M 0.01% 525
2024
Q1 		$741K Sell
50,000
-225,000
-82% -$2.62M ﹤0.01% 564
2023
Q4 		$2.24M Sell
275,000
-155,200
-36% -$812K 0.01% 430
2023
Q3 		$1.96M Buy
430,200
+155,200
+56% +$1.01M 0.02% 485
2023
Q2 		$1.94M Sell
275,000
-218,553
-44% -$1.56M 0.01% 509
2023
Q1 		$3.02M Buy
493,553
+185,553
+60% +$1.28M 0.02% 436
2022
Q4 		$1.97M Buy
308,000
+208,000
+208% +$1.62M 0.02% 610
2022
Q3 		$958K Hold
100,000
– – 0.01% 855
2022
Q2 		$1.1M Buy
100,000
+75,000
+300% +$983K 0.01% 907
2022
Q1 		$416K Buy
+25,000
New +$387K 0.01% 885

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

Hudson Bay Capital Management's IOVA Position: Q4 2024 in Review

Hudson Bay Capital Management sold out of Iovance Biotherapeutics (IOVA) in Q4 2024, closing a stake of 135,000 shares — an estimated $1.27M sold.

Hudson Bay Capital Management first reported a position in IOVA in Q1 2022 and held it in 11 quarters. The position peaked at $3.02M in Q1 2023. 301 funds tracked by Wall St. Rank hold IOVA as of Q4 2024.

  • Hudson Bay Capital Management reported no remaining Iovance Biotherapeutics position as of Q4 2024 after selling out during the quarter.
  • Hudson Bay Capital Management sold 135,000 Iovance Biotherapeutics shares in Q4 2024, an estimated $1.27M.
  • Hudson Bay Capital Management first reported a position in Iovance Biotherapeutics in Q1 2022 and held it in 11 quarters.
  • Hudson Bay Capital Management's Iovance Biotherapeutics position peaked at $3.02M in Q1 2023.
  • 301 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2024.

Based on Hudson Bay Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.